Microbot Medical Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, revealing a net loss of $3.6 million for the three months ending September 30, 2025, compared to a loss of $3.2 million in the same period of 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $9.7 million, up from $8.1 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $4.7 million from $4.6 million, and increased sales, general, and administrative expenses, which jumped to $5.9 million from $3.5 million. The company has not yet generated revenue from its operations.
In terms of liquidity, Microbot Medical reported a substantial increase in cash and cash equivalents, totaling $6.7 million as of September 30, 2025, compared to $3.1 million at the end of 2024. The company also holds marketable securities valued at $73.5 million, significantly up from $2.4 million at the end of the previous fiscal year. This increase in liquidity is primarily due to successful capital raising efforts, including approximately $83.7 million raised through various financing activities in 2025, compared to just $5.1 million in the same period of 2024.
Strategically, Microbot Medical has made notable advancements, including the FDA clearance for its LIBERTY® Endovascular Robotic Surgical System, which is designed for minimally invasive surgical procedures. The company has also expanded its operational capabilities, increasing its employee headcount to support commercialization efforts. As of September 30, 2025, Microbot had 67,158,044 shares of common stock outstanding, reflecting its ongoing efforts to raise capital through equity offerings.
The company has faced challenges due to geopolitical tensions in Israel, where its operations are primarily based. However, as of the filing date, Microbot reported no material adverse effects on its business operations. Looking ahead, the company anticipates continued losses as it invests in research and development and prepares for future commercialization of its products. Management believes that the available funds will be sufficient to support operations for at least the next twelve months, although it may seek additional capital through future equity or debt offerings.
About Microbot Medical Inc.
Microbot Medical Inc. develops minimally invasive robotic surgical devices, focusing on endovascular procedures. Its flagship LIBERTY system is a disposable, remotely operated robot designed to improve navigation, safety, and access in vascular interventions. The company targets global markets, including the U.S. and Europe, leveraging innovative technology, strategic partnerships, and regulatory approvals to establish its products as standards of care in interventional medicine.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.